Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: Ketamine under sedation for chronic pain and depression
NCT06317636Phase 4Active, not recruiting
- Sponsor
- Stanford University
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in chronic pain, major depressive disorder (MDD), sponsored by Stanford University. Started Jan 2025; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
chronic painmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06317636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317636.